You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
This lesson covers the ethical, social and legal issues surrounding genetic technology, as required by the Edexcel A-Level Biology specification (9BI0, Topic 7). You need to be able to evaluate arguments for and against various applications of genetic technology.
Advances in genetic technology have given humans unprecedented ability to read, modify and manipulate DNA. These technologies bring enormous potential benefits — curing genetic diseases, improving crop yields, advancing forensic science — but they also raise profound ethical questions about safety, consent, equity, and the limits of human intervention in nature.
In exam answers, you are expected to present balanced arguments, consider multiple perspectives, and support your points with specific examples.
| Argument | Explanation |
|---|---|
| Increased food production | GM crops can have higher yields, pest resistance (Bt crops) and drought tolerance, helping to feed a growing global population |
| Reduced pesticide use | Bt crops produce their own insecticide, reducing the need for chemical spraying and its environmental impact |
| Nutritional enhancement | Golden Rice contains beta-carotene to address vitamin A deficiency, which causes blindness in ~500,000 children per year |
| Medical applications | Recombinant insulin, growth hormone and clotting factors save lives |
| Environmental benefits | Herbicide-tolerant crops allow no-till farming, reducing soil erosion |
| Argument | Explanation |
|---|---|
| Gene flow | GM genes could spread to wild relatives via pollination, creating "superweeds" with herbicide resistance |
| Biodiversity loss | GM monocultures could reduce genetic diversity in crop species |
| Unknown long-term effects | Insufficient data on the long-term health effects of consuming GM foods |
| Corporate control | Large companies (e.g. Monsanto/Bayer) patent GM seeds, making farmers dependent and unable to save seeds |
| Labelling concerns | Consumers may not be informed about GM content in their food |
| Ecological impact | Bt toxin may harm non-target organisms (e.g. monarch butterfly larvae in proximity to Bt corn pollen) |
Exam Tip: When discussing GMOs, always give specific examples. Generic statements like "GMOs are bad for the environment" will not score well. Instead, explain the specific concern (e.g. "pollen from Bt corn may harm non-target Lepidoptera larvae") and the evidence for and against it.
Ethical status: Generally accepted as a medical treatment — analogous to organ transplantation or conventional medicine.
| In favour | Concerns |
|---|---|
| Treats serious genetic conditions (e.g. SCID, CF) | Risk of insertional mutagenesis (leukaemia in SCID trials) |
| Targets only the individual patient | Very expensive — raises issues of access and equity |
| Not inherited by offspring | May need repeated treatments (temporary effect) |
| Patient can give informed consent | Long-term effects uncertain |
Ethical status: Highly controversial; currently prohibited in many countries.
| In favour | Concerns |
|---|---|
| Could permanently eliminate a genetic disease from a family line | Future generations cannot consent to the modification |
| More efficient — treats all cells, not just affected tissues | Off-target effects could introduce harmful mutations into the gene pool |
| Prevents suffering before it occurs | Slippery slope towards "designer babies" and human enhancement |
| Irreversible — mistakes cannot be undone | |
| Could exacerbate social inequality if only available to the wealthy |
The development of CRISPR-Cas9 has made gene editing faster, cheaper and more accessible, intensifying ethical debates.
In November 2018, Chinese scientist He Jiankui announced that he had used CRISPR-Cas9 to edit the CCR5 gene in human embryos, creating the first gene-edited babies ("Lulu" and "Nana"). The aim was to make them resistant to HIV infection.
This was widely condemned because:
| Position | Arguments |
|---|---|
| Allow therapeutic editing | Could eliminate serious genetic diseases; CRISPR is more precise than previous methods; benefits outweigh risks if regulated |
| Prohibit all embryo editing | Too risky; off-target effects; consent issues; opens the door to enhancement and eugenics |
| Allow research only | Permits scientific understanding but prohibits clinical use until safety is established |
| International moratorium | Many scientists have called for a temporary halt until a global regulatory framework is agreed |
| Ethical consideration | Discussion |
|---|---|
| Informed choice | Parents have the right to information about their child's health |
| Termination decisions | Screening may lead to termination of pregnancies with genetic conditions, raising questions about the value placed on disabled lives |
| Pressure and anxiety | False positives cause unnecessary anxiety; social pressure may influence reproductive decisions |
| Disability rights | Some disability rights advocates argue that screening programmes send the message that disabled people are "unwanted" |
| In favour | Concerns |
|---|---|
| Prevents implantation of embryos with serious genetic conditions | Embryos are discarded — raises moral status of embryo questions |
| Avoids the need for later termination | Could be extended to select for non-medical traits (sex, eye colour) |
| Allows couples to have unaffected children | "Saviour siblings" — selecting an embryo that is a tissue match for an existing sick child raises concerns about instrumentalising children |
| Regulated in the UK by the HFEA (Human Fertilisation and Embryology Authority) | Expensive and not available to all — equity issues |
| Issue | Detail |
|---|---|
| Insurance | Genetic test results could be used by insurance companies to deny coverage or increase premiums |
| Employment | Employers could discriminate against individuals with genetic predispositions to disease |
| Data security | Genomic data stored in databases is vulnerable to breaches |
| Forensic databases | National DNA databases raise surveillance concerns; disproportionate representation of certain ethnic groups |
| Direct-to-consumer testing | Companies like 23andMe provide genetic data to consumers who may lack the knowledge to interpret results correctly |
In the UK, the Code on Genetic Testing and Insurance (2018) states that insurers may not require genetic test results for policies below a certain threshold, except for Huntington's disease for life insurance above £500,000.
Reproductive cloning (creating a genetically identical organism, as in Dolly the sheep) raises several concerns:
| Issue | Discussion |
|---|---|
| Animal welfare | Very low success rate; many failed attempts and abnormalities |
| Human cloning | Banned in most countries; raises concerns about identity, exploitation and dignity |
| Genetic diversity | Clones are genetically identical, reducing population diversity |
| Epigenetic effects | Cloned animals often have abnormal epigenetic patterns and health problems |
Therapeutic cloning (creating cloned embryos to harvest stem cells) is less controversial but still debated:
Genetic technology is regulated at multiple levels:
| Body | Role |
|---|---|
| HFEA (Human Fertilisation and Embryology Authority) | Regulates fertility treatment and embryo research in the UK |
| Nuffield Council on Bioethics | Independent advisory body on ethical issues in biology and medicine |
| WHO (World Health Organization) | International guidance on gene editing and genetic research |
| National legislation | UK Human Tissue Act (2004), EU GMO regulations, etc. |
Exam Tip: When discussing regulation, name the specific regulatory body where possible (e.g. HFEA for embryo research in the UK). This demonstrates detailed knowledge and strengthens your argument.
When evaluating the ethics of genetic technology in an exam, use this framework:
| Consideration | Questions to ask |
|---|---|
| Beneficence | Does it do good? Who benefits? |
| Non-maleficence | Could it cause harm? What are the risks? |
| Autonomy | Can those affected give informed consent? |
| Justice | Is access equitable? Who bears the costs and risks? |
| Rights | Are individual rights (privacy, bodily autonomy) respected? |
| Precautionary principle | Should we proceed cautiously where outcomes are uncertain? |
| Technology | Key ethical issues |
|---|---|
| GMOs | Gene flow, biodiversity, corporate control, food safety, labelling |
| Somatic gene therapy | Safety (insertional mutagenesis), cost, access, informed consent |
| Germ line gene therapy | Consent of future generations, designer babies, irreversibility |
| CRISPR | Off-target effects, embryo editing, enhancement vs therapy |
| Genetic screening | Termination decisions, disability rights, privacy, discrimination |
| Cloning | Animal welfare, human dignity, low success rate, genetic diversity |
| Genetic databases | Privacy, surveillance, data security, discrimination |
Exam Tip: Ethics questions are usually worth 6 marks or more and require a balanced discussion. Structure your answer with clear points for and against, use specific examples (Golden Rice, SCID gene therapy, He Jiankui), and conclude with a reasoned personal or scientific viewpoint.
This material sits in Edexcel 9BI0 Topic 8 (Grey Matter — Coordination, Response and Gene Technology), which expects candidates to evaluate the ethical, social and economic implications of gene technology — recombinant DNA, gene therapy, genetic screening and gene editing. The specification expects more than opinion: candidates must structure ethical reasoning using identifiable frameworks, name regulatory bodies, distinguish somatic from germline intervention, and ground their evaluation in specific case studies. Synoptic links run across the entire course. Lesson 5 (epigenetics and gene silencing) opens questions of transgenerational responsibility — if maternal famine, smoking or in-utero stress can leave epigenetic marks that affect grandchildren, how do we assign moral responsibility across generations? Lesson 7 (recombinant DNA) is the engineering substrate of the GM-crops debate and of every recombinant therapeutic protein (insulin, growth hormone, factor VIII). Lesson 8 (gene therapy and genetic screening) is the clearest somatic-vs-germline pivot — the He Jiankui (2018) germline case stands against the relatively uncontroversial somatic gene therapy that has cured ADA-SCID, restored sight in RPE65-mutant Leber congenital amaurosis (Luxturna) and treated spinal muscular atrophy (Zolgensma). Lesson 9 (genomics and bioinformatics) raises privacy, insurance, data sovereignty and reference-genome bias — particularly the structural under-representation of non-European populations in gnomAD and in clinical-grade variant databases. Synoptic links run sideways to Topic 6 (immunity, infection and biosecurity) — gain-of-function research on respiratory pathogens raised the same dual-use concerns the Asilomar conference (1975) raised for recombinant DNA — and to Topic 4 (biodiversity and evolution), where de-extinction proposals (woolly mammoth, passenger pigeon, thylacine) revive normative questions about whether scientific capability creates obligation. Refer to the official Pearson Edexcel 9BI0 specification document for exact wording.
Question (8 marks):
(a) The four-pillar framework of biomedical ethics — autonomy, beneficence, non-maleficence, justice — is widely used to structure the evaluation of new medical interventions. Apply this framework to the 2018 He Jiankui case, in which CRISPR-Cas9 was used to edit the CCR5 gene in human embryos with the stated aim of conferring HIV resistance. (6)
(b) Compare the four-pillar verdict on the He Jiankui case with the four-pillar verdict on a somatic gene therapy for ADA-SCID (severe combined immunodeficiency). Identify the pillar on which the two cases most clearly diverge. (2)
Solution with mark scheme:
(a) M1 (AO1) — autonomy. The four-pillar framework, articulated by Beauchamp and Childress, treats autonomy as the right of the individual to make informed decisions about interventions on their own body. In the He Jiankui case, the embryos — and the future children they would become — could not consent to a heritable genetic modification that would persist throughout their lifetimes and pass to all their descendants. The parents consented on the children's behalf, but parental proxy-consent for an irreversible germline change has no precedent in medical ethics; vaccination proxy-consent, by analogy, modifies somatic immunity only and is reversible across generations.
A1 (AO1) — beneficence. The principle of doing good asks what benefit the intervention confers. The stated aim was HIV resistance through CCR5 disruption — but prophylactic alternatives (condoms, pre-exposure prophylaxis, antiretroviral therapy of HIV-positive parents) already block vertical transmission with high effectiveness. The marginal benefit of germline CCR5 disruption was therefore near zero in expectation, not a serious advance over existing standard-of-care for the children involved.
A1 (AO2) — non-maleficence. The principle of doing no harm asks what risks the intervention imposes. CRISPR-Cas9 carries documented risks of off-target editing, on-target unintended deletions, and mosaicism (different cells of the same embryo carrying different edits). CCR5 itself has roles beyond HIV co-receptor function — the gene contributes to West Nile virus susceptibility, influenza outcomes and possibly cognitive function — so even a clean edit might produce unintended phenotypes. The risk-profile was poorly characterised, and the children carry these risks for life.
A1 (AO2) — justice. The principle of fair distribution asks who bears costs, risks and benefits. Germline editing at scale would be available only to families with access to CRISPR-equipped reproductive-medicine clinics, raising concerns about two-tier reproduction, "designer-baby" trajectories, and the historical eugenics legacy of state-sponsored sterilisation programmes (Indiana 1907, the Nazi T4 programme, US compulsory sterilisation that continued into the 1970s). Justice arguments do not require a slippery-slope claim to identify these structural inequities.
A1 (AO3) — synthesis. The four-pillar verdict on the He Jiankui case is negative across all four pillars: no autonomous consent, near-zero beneficence, substantial non-maleficence risk, and failure on justice. The international response — Chinese moratorium, He Jiankui's three-year prison sentence, WHO and Royal Society consensus statements, the second International Summit on Human Genome Editing condemning the work — reflects this convergent verdict and is itself evidence that genetic technology is shaped by ethical regulation, not driven solely by capability.
A1 (AO3) — framework limitations. The four-pillar framework is one tool among several. Consequentialist analysis weighs aggregate outcomes; deontological analysis identifies inviolable duties (non-instrumentalisation of children); virtue-ethics asks what a wise practitioner would do. Sophisticated answers note that bioethics is plural, not a single algorithm — and that the He Jiankui case fails on every framework, not only the four-pillar one.
(b) M1 (AO3) — somatic ADA-SCID gene therapy. The same four pillars yield a markedly different verdict: autonomy is satisfied (the patient or their parents consent for a single individual, with no germline transmission); beneficence is high (untreated ADA-SCID is fatal in early infancy; gene therapy restores immune function); non-maleficence carries documented risks (early SCID-X1 trials caused leukaemia in some patients, prompting safer integrating-vector design) but those risks are tractable and offset by the alternative of certain death; justice concerns persist around cost (~£1.5–2 million per Strimvelis / similar therapies) but are addressable through reimbursement reform.
A1 (AO3) — divergence. The pillar on which the two cases most clearly diverge is autonomy. Somatic gene therapy on a consenting (or proxy-consented) patient modifies only that patient. Germline editing modifies the children's children's children — a population that cannot be consulted at any point. Autonomy is the irreducible ethical hinge that distinguishes somatic from germline intervention.
Total: 8 marks (M2 A6).
Question (6 marks): A national bioethics commission is reviewing whether to permit clinical trials of CRISPR germline editing to prevent inherited beta-thalassaemia in families where both parents are homozygous carriers. (i) Identify two ethical arguments in favour, (ii) two arguments against, and (iii) discuss the role of regulatory bodies (HFEA, Nuffield Council, WHO) in the decision.
Mark scheme decomposition by AO:
| Mark | AO | Earned by |
|---|---|---|
| 1 | AO1.1 | Naming the four-pillar framework or another structured ethics tool (consequentialist, deontological, virtue) |
| 2 | AO1.2 | Distinguishing somatic (non-heritable, accepted clinically) from germline (heritable, currently prohibited in most jurisdictions) editing |
| 3 | AO2.1 | Argument in favour: would eliminate a serious heritable disease across the family line; for two homozygous parents, all children inherit beta-thalassaemia, so PGD with embryo selection cannot help — germline editing is the only route to an unaffected biological child |
| 4 | AO2.7 | Argument against: off-target risk, mosaicism, and the autonomy problem of editing a person who cannot consent — combined with the slippery-slope concern that therapeutic precedent paves the way for enhancement |
| 5 | AO3.1 | Identifying HFEA as the UK regulatory body for embryo research, Nuffield Council on Bioethics as the UK independent advisory body, and WHO as the international consensus-building body |
| 6 | AO3.2 | Synoptic — connecting to lesson 8 (somatic gene therapy as the ethically tractable contrast), lesson 7 (recombinant DNA as the historical Asilomar precedent for moratorium-based governance), and the He Jiankui case as the cautionary precedent that shaped current consensus |
Total: 6 marks (AO1 = 2, AO2 = 2, AO3 = 2). Edexcel reliably tests ethics through case-based prompts that demand a structured framework, named regulators and synoptic integration. Candidates who answer with personal opinion alone — "I think this is wrong because…" — lose the AO marks for structured reasoning. A* candidates name the four-pillar framework explicitly, distinguish somatic from germline, name HFEA / Nuffield / WHO, and locate the case in the Asilomar / He Jiankui regulatory genealogy.
Lesson 5 (epigenetics and gene silencing). Transgenerational epigenetic inheritance (the Dutch Hunger Winter cohort, the Överkalix Swedish cohort) raises ethical questions of intergenerational responsibility — if a pregnant woman's exposures can affect grandchildren through sperm-and-egg epigenetic marks, the locus of responsibility extends across generations in a way classical genetics did not. This complicates the simple somatic / germline binary that ethics classically assumed.
Lesson 7 (recombinant DNA and GM crops). The Asilomar conference (1975) is the foundational case study in scientific self-regulation — a voluntary moratorium by recombinant-DNA researchers, followed by the NIH Recombinant DNA Advisory Committee governance framework. Asilomar set the precedent for moratoria as a regulatory tool and is the institutional ancestor of the He Jiankui-era calls for international consensus on germline editing. The GM-crops debate adds the dimensions of corporate concentration (seed-patent regimes), gene flow (transgenes escaping into wild relatives) and regulatory divergence between US permissive and EU restrictive regimes.
Lesson 8 (gene therapy and genetic screening). Somatic gene therapy is the ethically tractable contrast case: ADA-SCID gene therapy (Strimvelis), Luxturna (RPE65 retinal dystrophy), Zolgensma (SMA) and Casgevy (CRISPR-edited autologous stem cells for sickle-cell disease and beta-thalassaemia) all modify the patient only, with conventional consent and tractable justice questions about cost. Germline editing is the contested case. The somatic / germline pivot is the cleanest single distinction in the topic.
Lesson 9 (genomics and bioinformatics). Population-scale sequencing raises privacy (genomic data are uniquely identifying), insurance (genetic discrimination concerns; UK 2018 Code on Genetic Testing and Insurance), forensic-database equity (UK National DNA Database over-represents certain ethnic groups), reference-genome bias (gnomAD heavily European, leading to over-classification of non-European variants as "rare" or "of uncertain significance") and Indigenous data sovereignty (the Havasupai case in Arizona, where samples collected for diabetes research were used for unconsented schizophrenia and ancestry studies; the resulting tribal lawsuit and settlement reshaped consent practice in population genomics).
Topic 4 (biodiversity and de-extinction). Proposals to de-extinct the woolly mammoth (Colossal Biosciences), thylacine and passenger pigeon raise the ought-from-can question explicitly: scientific capability does not create normative obligation. Questions of ecological niche reintegration, animal-welfare in surrogate-pregnancy hosts, and resource-allocation against conservation of extant species frame the debate. The four-pillar framework adapts: beneficence (ecosystem restoration claims) vs non-maleficence (welfare of cloned individuals; risk of disrupting current ecosystems) vs justice (philanthropic resource concentration on charismatic megafauna over extant biodiversity).
Topic 6 (biosecurity and dual-use research). Gain-of-function research on respiratory pathogens (the H5N1 ferret-transmissibility studies in 2011–2012; the lab-leak hypothesis discussion around SARS-CoV-2 origins) raises the same dual-use concerns Asilomar raised for recombinant DNA. The 2014–2017 US gain-of-function moratorium, the 2024 US Office of Science and Technology Policy guidance and the NIH Dual Use Research of Concern framework all draw on the Asilomar institutional legacy. Genetic-technology ethics are not a separate field from biosecurity ethics; they share a regulatory genealogy.
Historical eugenics and contemporary justice. Forced-sterilisation programmes — Indiana (1907), the Nazi T4 programme (1939–1945), US compulsory sterilisation continuing into the 1970s in some states, Sweden's Lebensborn-era programmes — are the historical cautionary cases that justice arguments draw on. The Universal Declaration on the Human Genome and Human Rights (UNESCO 1997) and the Council of Europe Oviedo Convention (1997) are the post-eugenic legal architecture. Modern designer-baby concerns are not abstract slippery-slope claims; they sit on a documented 20th-century history of state-sponsored genetic coercion.
Indigenous data sovereignty. Population-genomics projects historically extracted samples from Indigenous communities — Havasupai (Arizona), Aboriginal Australian, Māori, San — under consent frameworks now recognised as inadequate. The CARE Principles for Indigenous Data Governance (Collective benefit, Authority to control, Responsibility, Ethics) and the Te Mata Ira Māori ethical guidelines now structure consent in population-genomics partnerships. This is the justice-pillar frontier of contemporary genetic-technology ethics.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.